Condition (MeSH)
Corneal Opacity
ClinicalTrials.gov lists 37 trials for Corneal Opacity or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
36 of the 37 trials are tagged with Corneal Opacity itself; the rest are tagged with a narrower condition beneath it.
When did Corneal Opacity trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2/3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 2 |
| 2022 | 4 |
| 2021 | 1 |
| 2020 | 2 |
| 2018 | 3 |
| 2016 | 2 |
| 2015 | 3 |
| 2014 | 3 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Corneal Opacity trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2/3 | 1 |
| Phase 4 | 2 |
| Not applicable | 17 |
| Observational | 16 |
How many Corneal Opacity trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 1 |
| Completed | 16 |
| Terminated | 6 |
| Withdrawn | 3 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Corneal Opacity trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| CorNeat Vision Ltd. | 2 |
| The S.N. Fyodorov Eye Microsurgery State Institution | 2 |
| CENTOGENE GmbH Rostock | 1 |
| Fondation Ophtalmologique Adolphe de Rothschild | 1 |
Which drugs are being tested for Corneal Opacity? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Nepafenac | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Anti-Rejection Agents | 1 |
| Fluorometholone 1% topical ocular steroid | 1 |
| Prednisolone Acetate 1% Oph Susp | 1 |
| Low dose losartan | 1 |
| Mitomycin C 0.02% | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Corneal Opacity trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Choroidal detachment and exudative detachment | 1 | 1 |
| Conjunctival retraction with dehiscence of prosthesis & possible corneal epithelial ingrowth | 1 | 1 |
| Covid 19 Infection | 1 | 1 |
| Dehiscence of prosthesis superiorly | 1 | 1 |
| Exposure of implant | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Corneal Opacity? (62)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Topical Losartan for Treating Corneal Haze After Ultraviolet-A/Riboflavin Collagen Cross-Linking. | Cornea | 2024 | Yes |
| Global Trends in Blindness and Vision Impairment Resulting from Corneal Opacity 1984-2020: A Meta-analysis. | Ophthalmology | 2023 | Yes |
| Topical Losartan Decreases Myofibroblast Generation But Not Corneal Opacity After Surface Blast-Simulating Irregular PTK in Rabbits. | Translational vision science & technology | 2023 | Yes |
| Corneal Opacity: Cell Biological Determinants of the Transition From Transparency to Transient Haze to Scarring Fibrosis, and Resolution, After Injury. | Investigative ophthalmology & visual science | 2022 | Yes |
| Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience. | Journal of refractive surgery (Thorofare, N.J. : 1995) | 2022 | Yes |
Showing 5 of 62 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.